PDCD1 and neoplasm: Furthermore, the study unveiled the expression of the checkpoint marker LAG3 in tumor-infiltrating immune cells, suggesting its potential as a candidate for immune checkpoint blockade in high-risk UM patients, who typically demonstrate poor response to PD1 and CTLA4 checkpoint inhibitors.